Test Code MCFRC MayoComplete Renal Cell Carcinoma with Fibromyomatous Stroma Panel, Next-Generation Sequencing, Tumor
Ordering Guidance
Multiple oncology (cancer) gene panels are available. For more information see Hematology, Oncology, and Hereditary Test Selection Guide.
Necessary Information
A pathology report (final or preliminary), at minimum containing the following information, must accompany specimen for testing to be performed:
1. Patient name
2. Block number-must be on all blocks, slides, and paperwork (can be handwritten on the paperwork)
3. Tissue collection date
4. Source of the tissue
Specimen Required
This assay requires at least 20% tumor nuclei.
-Preferred amount of tumor area with sufficient percent tumor nuclei: tissue 216 mm(2)
-Minimum amount of tumor area: tissue 36 mm(2)
-These amounts are cumulative over up to 10 unstained slides and must have adequate percent tumor nuclei.
-Tissue fixation: 10% neutral buffered formalin, not decalcified
-For specimen preparation guidance, see Tissue Requirement for Solid Tumor Next-Generation Sequencing. In this document, the sizes are given as 4 mm x 4 mm x 10 slides as preferred: approximate/equivalent to 144 mm(2) and the minimum as 3 mm x 1 mm x 10 slides: approximate/equivalent to 36 mm(2).
Preferred:
Specimen Type: Tissue block
Collection Instructions: Submit a formalin-fixed, paraffin-embedded tissue block with acceptable amount of tumor tissue.
Acceptable:
Specimen Type: Tissue slide
Slides: 1 Stained and 10 unstained
Collection Instructions: Submit 1 slide stained with hematoxylin and eosin and 10 unstained, nonbaked slides with 5-micron thick sections of the tumor tissue.
Note: The total amount of required tumor nuclei can be obtained by scraping up to 10 slides from the same block.
Additional Information: Unused unstained slides will not be returned.
Specimen Type: Cytology slide (direct smears or ThinPrep)
Slides: 1 to 3 Slides
Collection Instructions: Submit 1 to 3 slides stained and coverslipped with a preferred total of 5000 nucleated cells, or a minimum of at least 3000 nucleated cells.
Note: Glass coverslips are preferred; plastic coverslips are acceptable but will result in longer turnaround times.
Additional Information: Cytology slides will not be returned.
Useful For
Identifying specific mutations within the ELOC (TCEB1), TSC1, TSC2, and VHL genes to assist in tumor diagnosis/classification
Assisting in the clinical management of patients with renal cell carcinoma
Special Instructions
Method Name
Sequence Capture Next-Generation Sequencing (NGS)
Reporting Name
MayoComplete Fibromyomatous RCCSpecimen Type
VariesSpecimen Minimum Volume
See Specimen Required
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Varies | Ambient (preferred) | ||
Refrigerated |
Reject Due To
Specimens that have been decalcified (all methods) Specimens that have not been formalin-fixed, paraffin-embedded, except for cytology slides Extracted nucleic acid (DNA/RNA) |
Reject |
Clinical Information
A subset of renal cell carcinoma commonly referred to as "renal cell carcinoma with fibromyomatous stroma" frequently shows overlapping morphologic and immunophenotypic features. These tumors are thought to arise secondary to alterations of ELOC (also referred to as TCEB1) and other MTOR (mechanistic target of rapamycin) pathway genes, such as TSC1 and TSC2. Furthermore, these tumors are unrelated to clear cell renal cell carcinoma that typically show alterations of the VHL gene (including epigenetic silencing, truncating alterations, and deletions). The 5th edition of the World Health Organization classification of tumors recognizes ELOC (TCEB1)-mutated renal cell carcinoma as a molecularly defined entity.(1) This assay, performed using formalin-fixed paraffin-embedded tissue or cytology material, is therefore helpful for establishing an accurate diagnosis and to define prognosis. It is important to note that this assay does not distinguish between germline and somatic alterations.
Reference Values
An interpretive report will be provided.
Day(s) Performed
Monday through Friday
Report Available
12 to 20 daysPerforming Laboratory
Mayo Clinic Laboratories in RochesterTest Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
88381-Microdissection, manual
81479
81406
81407
81404
81479 (if appropriate for government payers)
Forms
If not ordering electronically, complete, print, and send an Oncology Test Request (T729) with the specimen.